Sartorius Stedim Biotech Stock Working Capital
| SDMHF Stock | USD 205.68 0.68 0.33% |
Fundamental analysis of Sartorius Stedim allows traders to better anticipate movements in Sartorius Stedim's stock price by examining its financial health and performance throughout various phases of its business cycle.
Sartorius |
Sartorius Stedim Biotech Company Working Capital Analysis
Sartorius Stedim's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Based on the company's disclosures, Sartorius Stedim Biotech has a Working Capital of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Instruments & Supplies industry. The working capital for all United States stocks is 100.0% higher than that of the company.
Sartorius Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sartorius Stedim's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sartorius Stedim could also be used in its relative valuation, which is a method of valuing Sartorius Stedim by comparing valuation metrics of similar companies.Sartorius Stedim is currently under evaluation in working capital category among its peers.
Sartorius Fundamentals
| Return On Equity | 0.33 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 32.97 B | |||
| Shares Outstanding | 92.17 M | |||
| Shares Owned By Insiders | 73.81 % | |||
| Shares Owned By Institutions | 13.73 % | |||
| Price To Earning | 60.34 X | |||
| Price To Book | 13.58 X | |||
| Price To Sales | 9.62 X | |||
| Revenue | 2.89 B | |||
| Gross Profit | 1.55 B | |||
| EBITDA | 798.67 M | |||
| Net Income | 414.41 M | |||
| Cash And Equivalents | 161.7 M | |||
| Cash Per Share | 1.75 X | |||
| Total Debt | 521.07 M | |||
| Debt To Equity | 0.50 % | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 24.67 X | |||
| Cash Flow From Operations | 695.97 M | |||
| Earnings Per Share | 7.94 X | |||
| Price To Earnings To Growth | 3.43 X | |||
| Number Of Employees | 10.41 K | |||
| Beta | 0.45 | |||
| Market Capitalization | 34.9 B | |||
| Total Asset | 3.95 B | |||
| Z Score | 39.6 | |||
| Annual Yield | 0 % | |||
| Five Year Return | 0.50 % | |||
| Net Asset | 3.95 B |
About Sartorius Stedim Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sartorius Stedim Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sartorius Stedim using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sartorius Stedim Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| RYCEY | Rolls Royce Holdings | |
| VSAT | ViaSat Inc | |
| CIG | Companhia Energetica de | |
| ATEX | Anterix | |
| BBAI | BigBearai Holdings |
Other Information on Investing in Sartorius Pink Sheet
Sartorius Stedim financial ratios help investors to determine whether Sartorius Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.